Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Catalent, Inc. CTLT
$32.96
-$1.19 (-3.61%)
На 18:00, 12 мая 2023
+235.77%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
6230213550.00000000
-
week52high
115.34
-
week52low
32.41
-
Revenue
4828000000
-
P/E TTM
21
-
Beta
1.17474000
-
EPS
2.22000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:15
Описание компании
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | Outperform | 30 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 30 авг 2022 г. |
| Jefferies | Buy | Buy | 30 авг 2022 г. |
| Deutsche Bank | Hold | Hold | 30 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 04 мая 2022 г. |
| Barclays | Overweight | Overweight | 06 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 03 ноя 2022 г. |
| RBC Capital | Outperform | Outperform | 02 ноя 2022 г. |
| Keybanc | Overweight | Overweight | 02 ноя 2022 г. |
| B of A Securities | Neutral | Buy | 02 ноя 2022 г. |
| Barclays | Overweight | Overweight | 02 ноя 2022 г. |
| Argus Research | Hold | Buy | 07 ноя 2022 г. |
| Keybanc | Sector Weight | Overweight | 19 дек 2022 г. |
| Barclays | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hopson Ricky | D | 16452 | 643 | 23 янв 2023 г. |
| Boerman Manja | D | 15860 | 780 | 05 дек 2022 г. |
| Grippo Michael J | D | 17792 | 2451 | 31 окт 2022 г. |
| Zippelius Peter | A | 11979 | 4149 | 27 окт 2022 г. |
| MOREL DONALD E JR | A | 58462 | 4149 | 27 окт 2022 г. |
| STAHL JACK L | A | 36328 | 4149 | 27 окт 2022 г. |
| LUCIER GREGORY T | A | 25258 | 4149 | 27 окт 2022 г. |
| GREISCH JOHN J | A | 16880 | 4149 | 27 окт 2022 г. |
| Kreuzburg Christa | D | 13058 | 421 | 27 окт 2022 г. |
| Kreuzburg Christa | A | 13479 | 4149 | 27 окт 2022 г. |
Новостная лента
Why Catalent Stock Was in the Red Again Today
The Motley Fool
09 мая 2023 г. в 18:36
A pair of prognosticators pinged the company with price target cuts. One of the two went as far as to downgrade his recommendation, too.
Why Catalent Stock Was a Disaster Today
The Motley Fool
08 мая 2023 г. в 17:27
Investors expecting the contract drug specialist to publish its latest quarterly results on Tuesday were sorely disappointed. Once it does release results, the company will deliver weaker guidance than previously expected.
CTLT Stock Sinks 25% After Catalent Delays Earnings Release
InvestorPlace
08 мая 2023 г. в 14:57
A biotechnology firm that can't catch a break, Catalent (NYSE: CTLT ) added to its growing list of problems with a delay of its fiscal third-quarter earnings report. Originally, management scheduled the financial disclosure for today.
Why Wall Street Took a Hit From These 2 NYSE Stocks
The Motley Fool
08 мая 2023 г. в 12:43
Markets were mixed just after midday on Monday. Catalent delayed a key quarterly report filing, pointing to a big hit to revenue and profit.
Catalent Delays Earnings Report, Expects to 'Significantly' Cut Guidance
Barrons
08 мая 2023 г. в 09:09
Catalent anticipates a significant reduction to both its fiscal 2023 revenue and adjusted earnings before interest, taxes, depreciation and amortization guidance.